STERIS plc (STE) FinancialsSTESTERIS plc

STERIS plc (STE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service, accounting for 46.9% of total sales, equivalent to $745.00M. Other significant revenue streams include Consumables and Capital equipment. Understanding this composition is critical for investors evaluating how STE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, STERIS plc maintains a gross margin of 45.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.15%, while the net margin is 26.93%. These profitability ratios, combined with a Return on Equity (ROE) of 11.37%, provide a clear picture of how effectively STE converts its operational activities into shareholder value.

In the context of the broader market, STE competes directly with industry leaders such as WST and GH. With a market capitalization of $22.74B, it holds a significant position in the sector. When comparing efficiency, STE's gross margin of 45.84% stands against WST's 37.74% and GH's 65.39%. Such benchmarking helps identify whether STERIS plc is trading at a premium or discount relative to its financial performance.

Steris has shown consistent revenue growth, with Q1 2027 revenue of $1.5 billion reflecting a 7.9% increase year-over-year. The net income for the same quarter was $200.1 million, translating to an EPS of $2.04, which is a significant improvement from last year's $177.4 million and $1.79 per share.